Narcolepsy Market Size

Global Narcolepsy Market Overview

The Narcolepsy Market Size was valued at USD 2.43 Billion in 2023. The Global Narcolepsy industry is projected to grow from USD 2.59 Billion in 2024 to USD 7.28 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.26% during the forecast period (2024 - 2032). 

Narcolepsy can be understood as a medical condition that is characterized by overwhelming daytime drowsiness and experiencing sudden attacks of sleep. 

Sometimes, these chronic sleep disorders can lead to a sudden loss of muscle tone that is known as cataplexy. This leads to weakness and loss of muscle control, as well. Sleep paralysis and other issues like hallucinations, daytime sleepiness, fragmented sleep & insomnia, besides others are some of the most common symptoms of narcolepsy disease.

COVID 19 Analysis

The narcolepsy market has been one of the affected markets since the coronavirus infection has turned into a pandemic and is facing adversities ever since. The changing way of life and inclinations of individuals is a consequence of the pandemic that sped up a significant change in the useful examples of the market. The primary explanation for this is that the pandemic has introduced significant difficulties for industry and market verticles which are confronting issues to work. The inaccessibility of unrefined substance for the creation and assembling close by the strategic help nonattendance is pushing for a mass disturbance of the store network instrument. 

The examples of interest and assembling are distinctive in both the provincial and worldwide areas are vigorously affecting the capacity of the interest to work and the practical limitations that have been forced are likewise adding to the affliction.

Notwithstanding, to accomplish the past examples and advantage both the makers and interest groups, the public authority is putting resources into innovative work strategies to assist the narcolepsy market with growing a worldwide scale. Likewise, the key market players are and route to curating inventive and imaginative items and dispatching them for an enormous scope. This is being done to assist them with perceiving the items and requests according to the accessibility likewise.

The first major European market launch of Xyrem®, following the recent orphan approval by the European Commission for cataplexy in adult narcoleptic patients, occurred in 2006. The main symptom of narcolepsy is characterized by excessive sleepiness during the day as well as sleep attacks, which are sudden and irresistible urges to sleep during the day. 

Narcolepsy refers to an incurable neuropsychiatric disorder characterized by extreme daytime hypersomnolence associated with an intermittent, uncontrollable, overwhelming desire to sleep and periods of involuntary muscle weakness triggered by emotions such as surprise, laughter, anger, or excitement; it arises from episodes of unusual muscle relaxation called cataplexy that occur during waking hours. Emotional stimuli like joy, surprise, or stress can evoke this condition because it arises from the sudden loss of motor tone. Possible triggers include physical fatigue, excessive tiredness, or anxiety.

An authorized generic version of Jazz Pharmaceuticals' Xyrem (Sodium Oxybate) oral solution CIII was revealed by Amneal in December 2023. Sodium oxybate oral solution 0.5 g/mL is a central nervous system depressant therapy option for children aged greater than seven years old who have cataplexy or EDS due to narcolepsy. Moreover, Amneal has gained ANDA approvals from five complex generic products from the Food and Drug Administration. Dexmedetomidine injection was one of three recently approved injectables on the FDA’s shortage product list.

Jazz Pharma said it’s suing to have the Food and Drug Administration set aside the approval of Avadel Pharma’s Lumryz while seeking to protect its oxybate franchise against an emerging branded rival. Jazz maintains that its competitor’s drug launched earlier this month is just an extended-release reformulation of its own high-sodium oxybate product called Xyrem. The U.S. approved Lumryz on May 1 for treating cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Moreover, Jazz claims that Lumryz’s approval was unlawful because it violated Xywav’s orphan drug exclusivity. 

According to Jazz, Xywav is protected by orphan drug exclusivity (ODE), yet the FDA approved Lumryz and gave its competitor seven years of ODE on the basis that it made a significant contribution to patient care and thus is clinically superior to both Xywav and Xyrem. Therefore, the FDA wrongfully acted beyond its powers under the Orphan Drug Act, according to Jazz in an SEC filing.

Narcolepsy Market Trends

Drivers

The narcolepsy market size is witnessing the emergence of various market factors that will drive the global market towards growth amid the ongoing forecast period that will be ending in 2032. There has been an increase in the prevalence of narcolepsy and the growing degree of the obese population are the major drivers of narcolepsy market growth during the forecast period of 2024-2032. 

According to the stats that have been circulated by the Sleep Science journal in 2017, it was estimated that approximately 1 in every 2,000 people across the global scale lives with narcolepsy. Moreover, from the period, the Australian Institute of Health and Welfare stated that approximately two-thirds, i.e., 63% of the Australian population aged 18 years and more were estimated to be overweight or obese and had higher chances of contracting the disease.

Restraints

However, the narcolepsy market size is witnessing the emergence of factors that might restrain the market from growing as per the predictions for the market. There has been a reduced availability of information and awareness that will hamper the market from growing in the international market premises.

Technology Analysis

There has been a rising number of people who are suffering from a host of narcoleptic disorders, which are inclusive of hallucinations, sleep paralysis, disrupted nocturnal sleep, and obesity. These issues are prevalent that have caught the attention of governments around the world. This attention is forcing them to take the necessary steps to address this condition. For instance, there has been the establishment of awareness campaigns that are conducted by various networks, including the National Center on Sleep Disorders Research. These help to address the needs of individuals with serious or mild narcoleptic conditions.

Study Objectives

• The narcolepsy market aims to have significant market experiences and outline close by the perspectives as advanced by the business chiefs and specialists to foresee the CAGR pace of development of the market and the market valuation during 2024-2032


• The market aims to concentrate on the extent of the market during the estimated time frame by seeing the market patterns and fragment execution in major geological locales of the globe. The market report aims to have a deep understanding based on which the global narcolepsy market has been segmented. The report further helps to understand the potential of the market segments to meet the rising needs of the people and help the market players understand the demand patterns so that they can produce and manufacture accordingly.


• The market report aims to have an outline of the serious degree winning in the market among the key market players during the period and break down the new improvements attempted by the local players for worldwide rivalry and competition amid the market operations that are at different stages of completion during the ongoing forecast period that will be ending in 2032.

Narcolepsy Market Segment Insights